Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
May 2012, Vol 3, No 3
May 2012, Vol 3, No 3
Mevion S250 Proton Therapy System Lowers Costs, Approved in Europe
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
The Mevion S250 Proton Therapy System has received marketing approval in Europe but is still pending clearance by the US Food and Drug Administration.
Read Article
Vaccine Showing Antitumor Activity: A New Paradigm in Cancer Therapy?
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
Injecting antibodies and T cells with cancer stem cells may signal a new paradigm for anticancer immunotherapy, according to a recent study.
Read Article
NIH Awards $10.5 Million to New Technologies for the Study of Molecular Genes
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has awarded $10.5 million to 10 researchers to develop technologies that will assist research on millions of genomic elements that play a role in determining what genes are expressed, and at what levels in different cells.
Read Article
New Collaboration to Enhance Personalized Cancer Drug Development
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
Genomic Health announced it has formed an alliance with OncoMed Pharmaceuticals to support the development of DNA-sequencing technologies in the search for diagnostic biomarkers that could identify patients who will best benefit from targeted drugs currently in development by OncoMed.
Read Article
Oncologists Should Weigh “Value” in Their Clinical Decisions
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
A recent survey of US and Canadian oncologists explored how they perceive cost-effectiveness of the new and costly cancer treatments, and whether providers are considering value questions of quality versus cost in their clinical decisions.
Read Article
NIH: Offer Active Surveillance to Men with Localized Prostate Cancer
In the Literature
May 2012, Vol 3, No 3
The National Institutes of Health (NIH) convened a State-of-the-Science Conference to assess the evidence regarding observational strategies as an alternative to immediate treatment for localized prostate cancer (Ganz PA, et al.
Ann Intern Med
. 2012;156:591- 595).
Read Article
PSA Screening Reduces Prostate Cancer, but Not All-Cause, Mortality
In the Literature
May 2012, Vol 3, No 3
Controversy abounds regarding the question of whether routine prostate-specific antigen (PSA) testing reduces mortality from prostate cancer.
Read Article
Cancer Therapies Given Preferential Status over Other Diseases in Assessing Value
In the Literature
May 2012, Vol 3, No 3
Cancer is the most dreaded of all diseases, the authors of a new study suggest, which may explain why policymakers have sometimes given cancer therapies preferential status over therapies for other conditions (Neumann PJ, et al.
Health Aff [Millwood]
. 2012;31:700-708).
Read Article
Are Higher Costs of Cancer Care in the United States versus Europe Worth It?
In the Literature
May 2012, Vol 3, No 3
The United States spends more on cancer care than European countries. Some people have argued that this extra expense is unwarranted, because US patients with cancer have similar or worse outcomes despite this increased spending. However, data from a new study suggest that the higher spending for cancer in the United States than in 10 European countries may be worth the additional expense (Philipson T, et al.
Health Aff [Millwood]
. 2012;31:667-675).
Read Article
Afinitor First Drug Indicated for Noncancerous Kidney Tumors
FDA Approvals, News & Updates
May 2012, Vol 3, No 3
The FDA accelerated the approval of the oral mTOR kinase inhibitor everolimus (Afinitor; Novartis) for the treatment of kidney tumors (ie, renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex (TSC).
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma